Register Partnership Interest

Partners had an opportunity to get ahead of the curve and position their company at the forefront of the minds of leading pharma and pioneering biotech at the 7th Obesity & NASH Drug Development Summit; dedicated to pushing the boundaries in cutting-edge metabolic research and drug development using contract research, multi-omics, in vivo and in vitro models, digital pathology, artificial intelligence, and non-invasive biomarkers.

Partners had the opportunity to showcase their brand and capitalize on our audience of leading companies with active pipelines in NASH and obesity.

Why Do Partners Return?

Regeneron, Amgen, Gilead, Inventiva, Akero Therapeutics and AstraZeneca are amongst our other 160+ attendees that were seeking partners to help them in the following areas:

Contract Research – accelerate and support preclinical and clinical R&D and position yourself as the leading CRO in metabolic syndromes

Non-Invasive Biomarkers– communicate your capabilities to enhance the development and validation of blood-based, serum, predictive and imaging biomarkers to demonstrate benefit beyond bariatric surgery

Digital Pathology – demonstrate your expertise in quantifying details of fibrosis dynamics with novel insights into treatment-induced fibrosis regression in NASH to accurately diagnose and treat patients

Discovery & Omics – aid industry in clarifying the route towards anti-obesity treatments by offering your services in genotyping of patients and omics-type analyses

Who Did You Miss:

MicrosoftTeams-image (44)
MicrosoftTeams-image (45)
MicrosoftTeams-image (40)